Adjuvanted flu: not just a 65+ vaccine anymore?
New US modeling puts a number on extending adjuvanted influenza vaccine (aTIV/aQIV) use down to age 50 - just as Moderna's mRNA-1010 and Sanofi's Fluzone HD both pursue regulatory pathways into the very same age band.
McGovern I, Flores R, Haag MDM. Potential to Avert Additional Influenza Burden in the United States with Use of Adjuvanted vs. Standard Influenza Vaccines in Individuals 50-64 Years of Age. Vaccines 2026;14(5):380. PMID 42188753. Sample from MarketVIEW: Seasonal influenza vaccines (CAT VAMV036).
per +5% rVE gain, ages 50-64
per +5% rVE gain (avg./season)
per +5% rVE gain (avg./season)
per +5% rVE gain (avg./season)
The timing is not a coincidence. Days after the FDA's VRBPAC voted 9-0 on 18 June 2026 that Moderna's mRNA-1010 (mFLUSIVA) benefits outweigh its risks for adults 50+, this CSL Seqirus-authored modeling makes its own quantified case for widening adjuvanted vaccine use into the same 50-64 age band. Moderna's own regulatory path splits by age - traditional approval built on direct efficacy for 50-64, accelerated approval leaning on immunogenicity for 65+ - almost a mirror image of where the hard evidence currently sits for adjuvanted vaccines. FDA decision (PDUFA) due 5 August 2026. Sanofi has its own move in motion too: the FDA and EMA have accepted for review its submission to extend Fluzone High-Dose/Efluelda to adults 50 and above, backed by a completed head-to-head Phase 3 trial - though the company's own guidance points to a regulatory decision around 2027.
In adults 65+, adjuvanted vaccines already outperform standard dose
The MF59-adjuvanted influenza vaccine (aTIV/aQIV) was designed to boost the immune response of older adults, and the real-world evidence backs it up: among adults aged 65 and over, aTIV/aQIV has shown 14% greater relative vaccine effectiveness than standard-dose TIV/QIV. That comparative-effectiveness base is broad, direct, and already built into ACIP guidance and payer coverage - it is the evidence bar this new study is trying to extend down to a younger population.
Every +5 points of relative effectiveness compounds into a measurable public health return
Modeling five US influenza seasons, the authors found that on average, each 5-percentage-point increase in the relative effectiveness of aTIV/aQIV vs. standard QIV prevented an additional average seasonal incremental burden of 15.2% (range 5.9%-37.2% across the seasons modeled). In absolute terms, per +5% rVE gain, that averages out to:
Bars indicate relative rank across outcomes, not a shared linear scale - figures span more than three orders of magnitude. All values are US, average per season, per +5% rVE gain.
A modeled case, published by the market leader, right as the age line moves
Deterministic sensitivity analysis found the greatest variability was tied to relative vaccine effectiveness and underlying burden estimates - exactly the two inputs a modeling exercise cannot observe directly. Probabilistic sensitivity results were normally distributed, which supports the central estimate but does not substitute for head-to-head efficacy data in this age band.
Three manufacturers, three evidence bases, three different clocks
This CSL Seqirus paper does not stand alone. By mid-2026, three of the largest players in US influenza vaccines were simultaneously pursuing the 50-64 age band - each starting from a different evidence base, and each running on a different regulatory clock.
The full modeling - and the wider adjuvanted-vaccine forecast
This is one modeled study inside a fast-moving market. The live MarketVIEW model tracks the adjuvanted and high-dose influenza vaccine landscape, the mRNA-1010 regulatory path, and the global seasonal influenza value & volume forecast to 2040. Excel forecast + executive presentation, updated for 2026.
View the seasonal influenza report ← Back to homepage